JP2014523882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523882A5 JP2014523882A5 JP2014517223A JP2014517223A JP2014523882A5 JP 2014523882 A5 JP2014523882 A5 JP 2014523882A5 JP 2014517223 A JP2014517223 A JP 2014517223A JP 2014517223 A JP2014517223 A JP 2014517223A JP 2014523882 A5 JP2014523882 A5 JP 2014523882A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- complement inhibitor
- medicament according
- complement
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161499895P | 2011-06-22 | 2011-06-22 | |
| US61/499,895 | 2011-06-22 | ||
| PCT/US2012/043845 WO2012178083A1 (en) | 2011-06-22 | 2012-06-22 | Methods of treating chronic disorders with complement inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018093590A Division JP2018138603A (ja) | 2011-06-22 | 2018-05-15 | 補体阻害剤による慢性障害の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523882A JP2014523882A (ja) | 2014-09-18 |
| JP2014523882A5 true JP2014523882A5 (cg-RX-API-DMAC7.html) | 2016-03-03 |
| JP6618682B2 JP6618682B2 (ja) | 2019-12-11 |
Family
ID=47422981
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517223A Active JP6618682B2 (ja) | 2011-06-22 | 2012-06-22 | 補体阻害剤による慢性障害の治療方法 |
| JP2018093590A Pending JP2018138603A (ja) | 2011-06-22 | 2018-05-15 | 補体阻害剤による慢性障害の治療方法 |
| JP2019218474A Pending JP2020045361A (ja) | 2011-06-22 | 2019-12-03 | 補体阻害剤による慢性障害の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018093590A Pending JP2018138603A (ja) | 2011-06-22 | 2018-05-15 | 補体阻害剤による慢性障害の治療方法 |
| JP2019218474A Pending JP2020045361A (ja) | 2011-06-22 | 2019-12-03 | 補体阻害剤による慢性障害の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10039802B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2723361B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6618682B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103796667A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2012272706B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013033272A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2840270C (cg-RX-API-DMAC7.html) |
| ES (1) | ES3044832T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL229950B (cg-RX-API-DMAC7.html) |
| MX (2) | MX379206B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012178083A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| US10125171B2 (en) | 2011-05-11 | 2018-11-13 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
| BR112013033272A2 (pt) | 2011-06-22 | 2020-11-10 | Apellis Pharmaceuticals, Inc. | composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos |
| AU2012304442B2 (en) | 2011-09-07 | 2017-05-25 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| ES2879430T3 (es) | 2012-11-15 | 2021-11-22 | Apellis Pharmaceuticals Inc | Análogos de compstatina de acción prolongada y composiciones y métodos relacionados |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| WO2014172560A1 (en) * | 2013-04-17 | 2014-10-23 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
| KR20240170595A (ko) | 2013-12-12 | 2024-12-03 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 성분 ｉＲＮＡ 조성물 및 이의 이용 방법 |
| AP2016009435A0 (en) | 2014-02-25 | 2016-09-30 | Achillion Pharmaceuticals Inc | Ether compounds for treatment of complement mediated disorders |
| WO2015152182A1 (ja) * | 2014-03-31 | 2015-10-08 | 日油株式会社 | 環状ベンジリデンアセタールリンカーを有する親水性ポリマー誘導体 |
| WO2016019888A1 (zh) * | 2014-08-07 | 2016-02-11 | 深圳华大基因科技有限公司 | 筛选纳米抗体的方法及系统 |
| EP3227683B1 (en) * | 2014-12-05 | 2019-04-24 | Nestec S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
| WO2016200627A1 (en) * | 2015-06-09 | 2016-12-15 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035362A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| FI3359555T3 (fi) * | 2015-10-07 | 2024-03-20 | Apellis Pharmaceuticals Inc | Annostusohjeet |
| AU2016344133A1 (en) * | 2015-10-30 | 2018-05-17 | Genentech, Inc. | Anti-Factor D antibody formulations |
| AU2017210042B2 (en) | 2016-01-20 | 2021-01-21 | 396419 B.C. Ltd. | Compositions and methods for inhibiting Factor D |
| KR20180128941A (ko) * | 2016-03-31 | 2018-12-04 | 오메로스 코포레이션 | 혈관 형성의 억제를 필요로 하는 대상체에서 혈관 형성을 억제하는 방법 |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| CN107019793B (zh) * | 2017-02-27 | 2019-12-24 | 新乡医学院 | MBL在制备预防或治疗Th17细胞引发疾病药物中的应用 |
| MX2019010381A (es) | 2017-03-01 | 2020-01-21 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos. |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| JP2020516607A (ja) | 2017-04-07 | 2020-06-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 投与レジメンならびに関連組成物および方法 |
| EP3612206A1 (en) * | 2017-04-21 | 2020-02-26 | Volution Immuno Pharmaceuticals SA | Coversin for the treatment of cicatrising eye inflammatory disorders |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| IL269895B2 (en) | 2017-04-21 | 2024-06-01 | Volution Immuno Pharmaceuticals Sa | Coversin for the treatment of autoimmune blistering diseases |
| WO2019022986A1 (en) * | 2017-07-24 | 2019-01-31 | Vitrisa Therapeutics, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR |
| WO2019028284A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA |
| CN107463795A (zh) * | 2017-08-02 | 2017-12-12 | 南昌大学 | 一种识别酪氨酸翻译后修饰位点的预测算法 |
| WO2019089653A1 (en) * | 2017-10-30 | 2019-05-09 | Apellis Pharmaceuticals, Inc. | Treatment of disorders |
| EP3717004A4 (en) | 2017-12-01 | 2021-12-01 | Children's Hospital Medical Center | COMPOSITIONS FOR BLOCKING INTERERONS AND THEIR METHODS OF USE |
| WO2019118938A1 (en) | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| PL3645550T3 (pl) | 2018-04-06 | 2022-04-04 | The Trustees Of The University Of Pennsylvania | Analogi kompstatyny o zwiększonej rozpuszczalności i ulepszonych właściwościach farmakokinetycznych |
| CN109078168B (zh) * | 2018-07-26 | 2019-09-06 | 广西医科大学第一附属医院 | 靶向补体抑制剂在制备改善脑死亡供肝药物中的应用 |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| MX2021002640A (es) | 2018-09-06 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| MX2021003425A (es) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| AU2019406830A1 (en) | 2018-12-17 | 2021-07-08 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| JP7676377B2 (ja) | 2019-10-22 | 2025-05-14 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体成分Ｃ３ ｉＲＮＡ組成物およびその使用方法 |
| US20250197403A1 (en) | 2020-02-20 | 2025-06-19 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| WO2021222549A1 (en) | 2020-04-30 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
| US20230172930A1 (en) | 2020-05-12 | 2023-06-08 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
| US11918624B2 (en) | 2020-06-10 | 2024-03-05 | Kelsius Laboratories LLC | Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders |
| WO2022066774A1 (en) | 2020-09-23 | 2022-03-31 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| EP4274896A1 (en) | 2021-01-05 | 2023-11-15 | Alnylam Pharmaceuticals, Inc. | Complement component 9 (c9) irna compositions and methods of use thereof |
| WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
| KR20240095325A (ko) | 2021-10-29 | 2024-06-25 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 인자 b (cfb) irna 조성물 및 이의 사용 방법 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US22260A (en) | 1858-12-07 | Improvement in saw-sets | ||
| FR2295746A1 (fr) | 1974-12-23 | 1976-07-23 | Francaise Coop Pharma | Nouveaux derives du tryptophane a activite nerveuse centrale renforcee |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| IT1179866B (it) | 1984-12-12 | 1987-09-16 | Rotta Research Lab | Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono |
| US4576750A (en) | 1985-04-22 | 1986-03-18 | Merck & Co., Inc. | Tryptophan derivative |
| US5157110A (en) | 1988-08-20 | 1992-10-20 | The Government Of The United States Of America | Synthetic, anti-complement protein |
| US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| EP0512733A2 (en) | 1991-05-03 | 1992-11-11 | Washington University | Modified complement system regulator |
| US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| US5776970A (en) | 1994-04-28 | 1998-07-07 | Yeda Research And Development Co. Ltd. | Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| WO1997033603A1 (en) | 1996-03-13 | 1997-09-18 | Trustees Of The University Of Pennsylvania | Novel peptides which inhibit complement activation |
| US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| WO1997047321A1 (en) | 1996-06-14 | 1997-12-18 | The Johns Hopkins University School Of Medicine | Use of chimeric vaccinia virus complement control proteins to inhibit complement |
| JPH1087700A (ja) | 1996-06-17 | 1998-04-07 | Smithkline Beecham Corp | Ｃ３ａ受容体およびＣ３ａを用いる治療およびスクリーニング方法 |
| CA2286692A1 (en) | 1997-04-11 | 1998-10-22 | President And Fellows Of Harvard College | Polymeric conjugates polyvalently presenting an agent for therapy |
| AU6957098A (en) | 1997-04-11 | 1998-11-11 | Advanced Medicine, Inc. | Polyvalent presenter combinatorial libraries and their uses |
| US6676943B1 (en) | 1997-04-24 | 2004-01-13 | Regents Of The University Of Minnesota | Human complement C3-degrading protein from Streptococcus pneumoniae |
| AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| AU756490B2 (en) | 1997-08-26 | 2003-01-16 | Abgenix, Inc. | A process for inhibiting complement activation via the alternative pathway |
| US6169057B1 (en) | 1997-09-04 | 2001-01-02 | The Regents Of The University Of California | Use of tryptophan and analogs as plant growth regulators |
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| WO1999044625A1 (en) | 1998-03-03 | 1999-09-10 | John Hopkins University | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| US6214790B1 (en) | 1998-04-10 | 2001-04-10 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| CA2360233A1 (en) | 1999-02-09 | 2000-08-17 | 3-Dimensional Pharmaceuticals, Inc. | Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor |
| AU4369000A (en) | 1999-04-26 | 2000-11-10 | Duke University | Inhibition of complement action |
| GB9930659D0 (en) | 1999-12-24 | 2000-02-16 | Bio Discovery Ltd | Inhibitors of complement activation |
| DK1265929T3 (da) | 2000-03-23 | 2009-11-16 | Genentech Inc | Anti-C2/C2a-inhibitorer til komplement aktivering |
| JP2004522410A (ja) | 2000-08-01 | 2004-07-29 | アムジェン インコーポレーテッド | Ｃ３ｂ／Ｃ４ｂ補体レセプター様分子およびその使用 |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| PT1325033E (pt) | 2000-10-10 | 2010-04-15 | Genentech Inc | Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda |
| CA2433335C (en) | 2000-12-29 | 2010-04-20 | Advanced Inhalation Research, Inc. | Particles for inhalation having sustained release properties |
| JP2005538953A (ja) | 2002-05-28 | 2005-12-22 | ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド | 新規チオフェンアミジン、それらの組成物、および補体媒介疾患および病気を治療する方法 |
| US20040092470A1 (en) | 2002-06-18 | 2004-05-13 | Leonard Sherry A. | Dry powder oligonucleotide formualtion, preparation and its uses |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| ES2373649T3 (es) | 2002-09-20 | 2012-02-07 | The Trustees Of The University Of Pennsylvania | Análogos de compstatina con actividad mejorada. |
| WO2004094600A2 (en) | 2003-04-16 | 2004-11-04 | The Texas A & M University System | Staphylococcus aureus efb protein and c3 binding region which inhibit complement activation |
| WO2004106369A2 (en) | 2003-06-02 | 2004-12-09 | Evolutec Limited | Complement inhibitors from ticks |
| EP1498422A1 (de) | 2003-07-17 | 2005-01-19 | Jerini AG | C5a-Rezeptor-Antagonisten |
| US7489726B2 (en) | 2003-08-13 | 2009-02-10 | Mitsubishi Electric Research Laboratories, Inc. | Resource-constrained sampling of multiple compressed videos |
| US7322498B2 (en) | 2003-09-10 | 2008-01-29 | The Ergo Baby Carrier, Inc. | Baby carrier |
| CA2579635A1 (en) | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
| US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| JP4960096B2 (ja) * | 2003-09-22 | 2012-06-27 | ペントラコール ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−６の生物学的効果を減じる化合物の使用 |
| JP5137053B2 (ja) | 2004-02-10 | 2013-02-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬 |
| EP2578683B9 (en) | 2004-02-12 | 2015-04-15 | Archemix LLC | Aptamer therapeutics useful in the treatment of complement-related disorders |
| EP1745033A4 (en) | 2004-05-08 | 2009-08-26 | Neurogen Corp | 2-ARYLPYRIMIDINES DISUBSTITUTED IN 4,5 |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2006042252A2 (en) | 2004-10-08 | 2006-04-20 | Potentia Pharmeceuticals, Inc. | Viral complement control proteins for eye disorders |
| EP1861114B1 (en) | 2005-03-11 | 2011-02-02 | Potentia Pharmaceuticals, Inc. | Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration |
| EP1739078A1 (de) | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| EP1893227A2 (en) * | 2005-06-06 | 2008-03-05 | Girish J. Kotwal | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
| GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2007034277A1 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists |
| WO2007034282A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
| WO2007034278A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Fused imidazole derivatives as c3a receptor antagonists |
| DK1951279T3 (en) | 2005-10-08 | 2017-07-31 | Apellis Pharmaceuticals Inc | COMPSTATIN AND ANALOGUES THEREOF FOR EYE DISEASES |
| JP5302004B2 (ja) | 2005-11-28 | 2013-10-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 強力なコンプスタチン類似体 |
| WO2008010902A2 (en) | 2006-07-06 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | Regulation of tlr signaling by complement |
| CA2671766A1 (en) | 2006-12-22 | 2008-07-03 | Encysive Pharmaceuticals, Inc. | Modulators of c3a receptor and methods of use thereof |
| PL2148691T3 (pl) | 2007-02-05 | 2015-12-31 | Apellis Pharmaceuticals Inc | Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego |
| EP2417974A1 (en) * | 2007-02-28 | 2012-02-15 | Schering Corporation | Combination therapy for treatment of immune disorders |
| AU2008221287A1 (en) * | 2007-03-01 | 2008-09-04 | Wellstat Immunotherapeutics, Llc | Treatment of diseases characterized by inflammation |
| WO2009029669A1 (en) | 2007-08-27 | 2009-03-05 | Novelmed Therapeutics, Inc. | Method of inhibiting complement activation with factor bb specific antibodies |
| WO2008151037A1 (en) | 2007-05-30 | 2008-12-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptide-based stat inhibitor |
| US20090048295A1 (en) | 2007-08-13 | 2009-02-19 | Joseph Kent Barbay | Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof |
| RU2505311C2 (ru) | 2007-10-02 | 2014-01-27 | Потентия Фармасьютикалз, Инк. | Пролонгированная доставка аналогов компстатина из гелей |
| JP2011509676A (ja) * | 2008-01-18 | 2011-03-31 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | ヒトＴｈ１７細胞の選択的分化、同定および調節 |
| PL2262831T3 (pl) | 2008-03-03 | 2015-08-31 | Novelmed Therapeutics Inc | Przeciwciała przeciwko properdynie |
| BRPI0921237A2 (pt) * | 2008-11-10 | 2015-09-22 | Alexion Pharma Inc | métodos e composições para o tratamento de distúrbios associados ao complemento |
| SG172338A1 (en) | 2008-12-22 | 2011-07-28 | Chemocentryx Inc | C5ar antagonists |
| GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| CA2760839C (en) * | 2009-05-01 | 2019-02-12 | The Trustees Of The University Of Pennsylvania | Modified compstatin with peptide backbone and c-terminal modifications |
| WO2010135717A2 (en) | 2009-05-21 | 2010-11-25 | Potentia Pharmaceuticals, Inc. | Complement assays and uses thereof |
| CN102597005A (zh) | 2009-06-23 | 2012-07-18 | 阿雷克森制药公司 | 与补体蛋白质结合的双特异性抗体 |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| WO2011100567A1 (en) * | 2010-02-11 | 2011-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic inhibition of granulocyte function in demyelinating disease |
| US8625635B2 (en) | 2010-04-26 | 2014-01-07 | Cleversafe, Inc. | Dispersed storage network frame protocol header |
| WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| ES2626182T3 (es) * | 2010-07-21 | 2017-07-24 | Eastern Virginia Medical School | Compuestos peptídicos para regular el sistema del complemento |
| JP6173911B2 (ja) * | 2010-09-10 | 2017-08-09 | メディミューン リミテド | 抗体誘導体 |
| WO2012040259A2 (en) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| BR112013033272A2 (pt) | 2011-06-22 | 2020-11-10 | Apellis Pharmaceuticals, Inc. | composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos |
| JP5878270B2 (ja) | 2012-12-19 | 2016-03-08 | プロメラス， エルエルシー | 高純度ノルボルネンアルカノールおよびその誘導体の製造方法 |
| WO2015023972A1 (en) * | 2013-08-16 | 2015-02-19 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| US9806963B2 (en) | 2013-10-18 | 2017-10-31 | Cellco Partnership | Feature activation on device |
| JP6815852B2 (ja) | 2016-11-30 | 2021-01-20 | Ntn株式会社 | 電動アクチュエータ用回転駆動源および電動アクチュエータ |
-
2012
- 2012-06-22 BR BR112013033272-7A patent/BR112013033272A2/pt not_active Application Discontinuation
- 2012-06-22 EP EP12803380.0A patent/EP2723361B1/en active Active
- 2012-06-22 JP JP2014517223A patent/JP6618682B2/ja active Active
- 2012-06-22 US US14/128,447 patent/US10039802B2/en active Active
- 2012-06-22 ES ES18212739T patent/ES3044832T3/es active Active
- 2012-06-22 CN CN201280036308.0A patent/CN103796667A/zh active Pending
- 2012-06-22 CA CA2840270A patent/CA2840270C/en active Active
- 2012-06-22 WO PCT/US2012/043845 patent/WO2012178083A1/en not_active Ceased
- 2012-06-22 EP EP18212739.9A patent/EP3524258B1/en active Active
- 2012-06-22 AU AU2012272706A patent/AU2012272706B2/en active Active
- 2012-06-22 MX MX2019003528A patent/MX379206B/es unknown
- 2012-06-22 MX MX2013014756A patent/MX363606B/es unknown
-
2013
- 2013-12-17 IL IL22995013A patent/IL229950B/en active IP Right Grant
-
2017
- 2017-09-27 AU AU2017235936A patent/AU2017235936B2/en active Active
-
2018
- 2018-05-15 JP JP2018093590A patent/JP2018138603A/ja active Pending
- 2018-06-29 US US16/023,383 patent/US20190192617A1/en not_active Abandoned
-
2019
- 2019-11-04 IL IL270406A patent/IL270406B/en unknown
- 2019-11-19 AU AU2019268066A patent/AU2019268066A1/en not_active Abandoned
- 2019-12-03 JP JP2019218474A patent/JP2020045361A/ja active Pending
- 2019-12-13 US US16/714,252 patent/US11013782B2/en active Active
-
2021
- 2021-04-20 US US17/235,281 patent/US11712460B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523882A5 (cg-RX-API-DMAC7.html) | ||
| ES2716906T3 (es) | Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab | |
| Cirak et al. | Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study | |
| Fanelli et al. | Neuromuscular blocking agent cisatracurium attenuates lung injury by inhibition of nicotinic acetylcholine receptor-α1 | |
| Lötvall et al. | 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids | |
| Kimura et al. | Toll-like receptor 3 stimulation causes corticosteroid-refractory airway neutrophilia and hyperresponsiveness in mice | |
| JP2016520573A5 (cg-RX-API-DMAC7.html) | ||
| AU2020202564A1 (en) | Methods for improving asthma symptoms using benralizumab | |
| ES2733602T3 (es) | Métodos para incrementar el volumen espiratorio forzado en pacientes asmáticos que usan benralizumab | |
| JP2016526050A5 (cg-RX-API-DMAC7.html) | ||
| Kubica et al. | IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study | |
| JP2023540096A (ja) | アロジェニック間葉系幹細胞によるアルツハイマー病の治療 | |
| Pacurari et al. | Idiopathic pulmonary comorbidities and mechanisms | |
| JP2023533658A (ja) | 急性呼吸窮迫症候群を治療又は予防する方法 | |
| Tasdemir et al. | Intravenous immunoglobulin for Guillain-Barré syndrome: how effective? | |
| RU2840902C2 (ru) | Способы нормализации симптомов астмы с применением бенрализумаба | |
| Ghosh et al. | Isotonic saline subjected to Taylor-Couette-Poiseuille flow demonstrates anti-inflammatory activity in a rat model of allergic asthma | |
| CN115944633A (zh) | PPAR-γ激动剂罗格列酮在睡眠呼吸暂停相关性高血压中的应用 | |
| Emeryk et al. | 197 The Effectiveness of two Different Methods of Salbutamol Nebulization in Children with Asthma | |
| Ogawa et al. | 195 The Impact of Administration of Leukotriene Receptor Antagonists, Pranlukast-EK to Infants with Bronchial Asthma |